Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 17/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 17/20 | 0.55 |
| ▸ | ITGAL | P20701 | 17/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201590 | 0.92 | ITGB2 (0.57) | ITGB2ICAM1ITGAL | |
| SCHEMBL5239341 | 0.82 | ITGAL (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL5204304 | 0.82 | ITGB2 (0.62) | ITGB2ICAM1ITGAL | |
| SCHEMBL5200790 | 0.82 | ITGAL (0.58) | ITGB2ICAM1ITGAL | |
| SCHEMBL5203590 | 0.72 | ITGAL (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL7970387 | 0.68 | ITGAL (0.57) | ITGB2ICAM1ITGAL | |
| SCHEMBL5201254 | 0.61 | ITGAL (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL2417808 | 0.60 | LMNA (0.53) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL18884091 | 0.59 | RAB9A (0.47) | L3MBTL1POLBALDH1A1MAPT | |
| SCHEMBL26024106 | 0.59 | POLB (0.44) | POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1284973-B1 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2007-06-27 | — | — | EP | claimed |
| US-6699888-B2 | ANTIINFLAMMATORY | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-02 | — | — | US | claimed |
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | US | claimed |
| EP-1284973-B1 | INHIBITORS OF ALPHA L BETA 2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-6699888-B2 | ANTIINFLAMMATORY | TANABE SEIYAKU CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225138-A1 | Inhibitors of alpha l beta 2 mediated cell adhesion | ICAM1, VCAM1, SELL | ITGB2 5/4885ICAM1 1/4885ITGAL 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.